{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:43:15Z","timestamp":1794850995239,"version":"4.9.1"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01651-1","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:53:25Z","timestamp":1778543605000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of hepatocyte epigenetics in the pathogenesis of metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Guangqi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqiu","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-8645","authenticated-orcid":false,"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"1651_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"1651_CR2","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song, S. J., Lai, J. C., Wong, G. L., Wong, V. W. & Yip, T. C. Can we use old NAFLD data under the new MASLD definition? J. Hepatol. 80, e54\u2013e56 (2024).","journal-title":"J. Hepatol."},{"key":"1651_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ueg2.12525","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng, J., Fan, J. G. & Francque, S. M. Therapeutic management of metabolic dysfunction associated steatotic liver disease. U. Eur. Gastroenterol. J. 12, 177\u2013186 (2024).","journal-title":"U. Eur. Gastroenterol. J."},{"key":"1651_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s43856-025-00796-9","volume":"5","author":"E Shumbayawonda","year":"2025","unstructured":"Shumbayawonda, E. et al. Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial. Commun. Med (Lond). 5, 74 (2025).","journal-title":"Commun. Med (Lond)"},{"key":"1651_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li, J. et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 4, 389\u2013398 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1651_CR6","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le, M. H. et al. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 20, 2809\u20132817.e28 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1651_CR7","first-page":"00036","volume":"S1043-2760","author":"L Miao","year":"2024","unstructured":"Miao, L., Targher, G., Byrne, C. D., Cao, Y. Y. & Zheng, M. H. Current status and future trends of the global burden of MASLD. Trends Endocrinol. Metab. S1043-2760, 00036\u20135 (2024).","journal-title":"Trends Endocrinol. Metab."},{"key":"1651_CR8","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/ANNALS-24-02933","volume":"178","author":"SMJ Ali","year":"2025","unstructured":"Ali, S. M. J. & Lai, M. Metabolic Dysfunction-Associated Steatotic Liver Disease. Ann. Intern Med. 178, ITC1\u2013ITC16 (2025).","journal-title":"Ann. Intern Med"},{"key":"1651_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher, G., Byrne, C. D. & Tilg, H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 73, 691\u2013702 (2024).","journal-title":"Gut"},{"key":"1651_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154320","volume":"111S","author":"N Perakakis","year":"2020","unstructured":"Perakakis, N., Stefanakis, K. & Mantzoros, C. S. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease. Metabolism 111S, 154320 (2020).","journal-title":"Metabolism"},{"key":"1651_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41392-023-01333-7","volume":"8","author":"YL Wu","year":"2023","unstructured":"Wu, Y. L. et al. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study. Signal Transduct. Target Ther. 8, 98 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1651_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41576-021-00438-5","volume":"23","author":"MH Fitz-James","year":"2022","unstructured":"Fitz-James, M. H. & Cavalli, G. Molecular mechanisms of transgenerational epigenetic inheritance. Nat. Rev. Genet. 23, 325\u2013341 (2022).","journal-title":"Nat. Rev. Genet"},{"key":"1651_CR13","doi-asserted-by":"publisher","first-page":"7571","DOI":"10.3390\/ijms21207571","volume":"21","author":"P Peixoto","year":"2020","unstructured":"Peixoto, P., Cartron, P. F., Serandour, A. A. & Hervouet, E. From 1957 to Nowadays: A Brief History of Epigenetics. Int J. Mol. Sci. 21, 7571 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"1651_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1152\/physrev.00002.2020","volume":"101","author":"DJ Hoffman","year":"2021","unstructured":"Hoffman, D. J., Powell, T. L., Barrett, E. S. & Hardy, D. B. Developmental origins of metabolic diseases. Physiol. Rev. 101, 739\u2013795 (2021).","journal-title":"Physiol. Rev."},{"key":"1651_CR15","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1007\/s12072-024-10667-5","volume":"18","author":"V Moretti","year":"2024","unstructured":"Moretti, V., Romeo, S. & Valenti, L. The contribution of genetics and epigenetics to MAFLD susceptibility. Hepatol. Int. 18, 848\u2013860 (2024).","journal-title":"Hepatol. Int"},{"key":"1651_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adc9653","volume":"15","author":"Y Xiao","year":"2023","unstructured":"Xiao, Y. et al. Hepatocytes demarcated by EphB2 contribute to the progression of nonalcoholic steatohepatitis. Sci. Transl. Med. 15, eadc9653 (2023).","journal-title":"Sci. Transl. Med"},{"key":"1651_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41586-019-1373-2","volume":"572","author":"Aizarani","year":"2019","unstructured":"Aizarani et al. A human liver cell atlas reveals heterogeneity and epithelial progenitors. Nature 572, 199\u2013204 (2019).","journal-title":"Nature"},{"key":"1651_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113869","volume":"176","author":"S Kumar","year":"2021","unstructured":"Kumar, S., Duan, Q., Wu, R., Harris, E. N. & Su, Q. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis. Adv. Drug Deliv. Rev. 176, 113869 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1651_CR19","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","volume":"114","author":"CP Day","year":"1998","unstructured":"Day, C. P. & James, O. F. Steatohepatitis: a tale of two \u201chits\u201d? Gastroenterology 114, 842\u2013845 (1998).","journal-title":"Gastroenterology"},{"key":"1651_CR20","doi-asserted-by":"crossref","unstructured":"Hardy, T., Oakley, F., Anstee, Q. M. & Day, C. P. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev. Pathol. 11, 451\u2013496 (2016).","DOI":"10.1146\/annurev-pathol-012615-044224"},{"key":"1651_CR21","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.3390\/nu15224757","volume":"15","author":"V Caputo","year":"2023","unstructured":"Caputo, V., Tarantino, G., Santini, S. J., Fracassi, G. & Balsano, C. The role of epigenetic control of mitochondrial (dys)function in masld onset and progression. Nutrients 15, 4757 (2023).","journal-title":"Nutrients"},{"key":"1651_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jceh.2019.11.011","volume":"10","author":"H Siddiqui","year":"2020","unstructured":"Siddiqui, H., Rawal, P., Bihari, C., Arora, N. & Kaur, S. Vascular endothelial growth factor promotes proliferation of epithelial cell adhesion molecule-positive cells in nonalcoholic steatohepatitis. J. Clin. Exp. Hepatol. 10, 275\u2013283 (2020).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"1651_CR23","doi-asserted-by":"publisher","first-page":"9196","DOI":"10.3390\/ijms23169196","volume":"23","author":"J Feng","year":"2022","unstructured":"Feng, J. et al. mTOR: a potential new target in nonalcoholic fatty liver disease. Int J. Mol. Sci. 23, 9196 (2022).","journal-title":"Int J. Mol. Sci."},{"key":"1651_CR24","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3390\/ijms20081948","volume":"20","author":"S Marchisello","year":"2019","unstructured":"Marchisello, S. et al. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J. Mol. Sci. 20, 1948 (2019).","journal-title":"Int J. Mol. Sci."},{"key":"1651_CR25","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"1651_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2331460","volume":"16","author":"R Bened\u00e9-Ubieto","year":"2024","unstructured":"Bened\u00e9-Ubieto, R., Cubero, F. J. & Nevzorova, Y. A. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD). Gut Microbes 16, 2331460 (2024).","journal-title":"Gut Microbes"},{"key":"1651_CR27","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/hep.24283","volume":"53","author":"S Sookoian","year":"2011","unstructured":"Sookoian, S. & Pirola, C. J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53, 1883\u20131894 (2011).","journal-title":"Hepatology"},{"key":"1651_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2022.08.022","volume":"78","author":"J Park","year":"2023","unstructured":"Park, J. et al. IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease. J. Hepatol. 78, 45\u201356 (2023).","journal-title":"J. Hepatol."},{"key":"1651_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2010.10.024","volume":"55","author":"C Dubuquoy","year":"2011","unstructured":"Dubuquoy, C. et al. Distinct regulation of adiponutrin\/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J. Hepatol. 55, 145\u2013153 (2011).","journal-title":"J. Hepatol."},{"key":"1651_CR30","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.1073\/pnas.1003585107","volume":"107","author":"Y Huang","year":"2010","unstructured":"Huang, Y. et al. A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc. Natl. Acad. Sci. USA 107, 7892\u20137897 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1651_CR31","doi-asserted-by":"publisher","first-page":"994","DOI":"10.14309\/ajg.0000000000001072","volume":"116","author":"E Vilar-Gomez","year":"2021","unstructured":"Vilar-Gomez, E. et al. Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD. Am. J. Gastroenterol. 116, 994\u20131006 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"1651_CR32","doi-asserted-by":"publisher","first-page":"439","DOI":"10.14218\/JCTH.2021.00286","volume":"10","author":"G Li","year":"2022","unstructured":"Li, G. et al. PNPLA3 rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. J. Clin. Transl. Hepatol. 10, 439\u2013448 (2022).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"1651_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/hep.28475","volume":"64","author":"M Eslam","year":"2016","unstructured":"Eslam, M. et al. International Liver Disease Genetics Consortium. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology 64, 34\u201346 (2016).","journal-title":"Hepatology"},{"key":"1651_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35158-9","volume":"13","author":"J Alharthi","year":"2022","unstructured":"Alharthi, J. et al. A metabolic-associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes. Nat. Commun. 13, 7430 (2022).","journal-title":"Nat. Commun."},{"key":"1651_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj0133","volume":"16","author":"Z Pan","year":"2024","unstructured":"Pan, Z. et al. Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease. Sci. Transl. Med. 16, eadj0133 (2024).","journal-title":"Sci. Transl. Med"},{"key":"1651_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004168","volume":"8","author":"A Bayoumi","year":"2021","unstructured":"Bayoumi, A. et al. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus. Adv. Sci. (Weinh). 8, 2004168 (2021).","journal-title":"Adv. Sci. (Weinh)"},{"key":"1651_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jhep.2018.10.021","volume":"70","author":"M Metwally","year":"2019","unstructured":"Metwally, M. et al. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3\u2019UTR. J. Hepatol. 70, 494\u2013500 (2019).","journal-title":"J. Hepatol."},{"key":"1651_CR38","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","volume":"378","author":"NS Abul-Husn","year":"2018","unstructured":"Abul-Husn, N. S. et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N. Engl. J. Med. 378, 1096\u20131106 (2018).","journal-title":"N. Engl. J. Med"},{"key":"1651_CR39","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1056\/NEJMoa2117872","volume":"387","author":"N Verweij","year":"2022","unstructured":"Verweij, N. et al. Germline Mutations in CIDEB and Protection against Liver Disease. N. Engl. J. Med. 387, 332\u2013344 (2022).","journal-title":"N. Engl. J. Med"},{"key":"1651_CR40","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/ng.3836","volume":"49","author":"M Eslam","year":"2017","unstructured":"Eslam, M. et al. International Liver Disease Genetics Consortium (ILDGC). IFN-\u03bb3, not IFN-\u03bb4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Nat. Genet 49, 795\u2013800 (2017).","journal-title":"Nat. Genet"},{"key":"1651_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7422","volume":"6","author":"M Eslam","year":"2015","unstructured":"Eslam, M. et al. International Hepatitis C Genetics Consortium (IHCGC). Interferon-\u03bb rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat. Commun. 6, 6422 (2015).","journal-title":"Nat. Commun."},{"key":"1651_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101111","volume":"50","author":"W Jonas","year":"2021","unstructured":"Jonas, W. & Sch\u00fcrmann, A. Genetic and epigenetic factors determining NAFLD risk. Mol. Metab. 50, 101111 (2021).","journal-title":"Mol. Metab."},{"key":"1651_CR43","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.3390\/ijerph18105227","volume":"18","author":"O Juanola","year":"2021","unstructured":"Juanola, O., Mart\u00ednez-L\u00f3pez, S., Franc\u00e9s, R. & G\u00f3mez-Hurtado, I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J. Environ. Res Public Health 18, 5227 (2021).","journal-title":"Int J. Environ. Res Public Health"},{"key":"1651_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.770504","volume":"8","author":"JS Rodr\u00edguez-Sanabria","year":"2022","unstructured":"Rodr\u00edguez-Sanabria, J. S., Escutia-Guti\u00e9rrez, R., Rosas-Campos, R., Armend\u00e1riz-Borunda, J. S. & Sandoval-Rodr\u00edguez, A. An update in epigenetics in metabolic-associated fatty liver disease. Front Med. (Lausanne) 8, 770504 (2022).","journal-title":"Front Med. (Lausanne)"},{"key":"1651_CR45","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymgme.2013.07.012","volume":"110","author":"V Iacobazzi","year":"2013","unstructured":"Iacobazzi, V., Castegna, A., Infantino, V. & Andria, G. Mitochondrial DNA methylation as a next-generation biomarker and diagnostic tool. Mol. Genet Metab. 110, 25\u201334 (2013).","journal-title":"Mol. Genet Metab."},{"key":"1651_CR46","doi-asserted-by":"publisher","first-page":"8138","DOI":"10.3390\/ijms21218138","volume":"21","author":"J Hyun","year":"2020","unstructured":"Hyun, J. & Jung, Y. DNA methylation in nonalcoholic fatty liver disease. Int J. Mol. Sci. 21, 8138 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"1651_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1053\/j.gastro.2022.09.027","volume":"164","author":"H Li","year":"2023","unstructured":"Li, H. et al. Hepatocyte adenosine kinase promotes excessive fat deposition and liver inflammation. Gastroenterology 164, 134\u2013146 (2023).","journal-title":"Gastroenterology"},{"key":"1651_CR48","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201950R","volume":"37","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation. FASEB J. 37, e22881 (2023).","journal-title":"FASEB J."},{"key":"1651_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101102","volume":"23","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. High glucose induces lipid accumulation via 25-hydroxycholesterol DNA-CpG methylation. iScience 23, 101102 (2020).","journal-title":"iScience"},{"key":"1651_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100063","volume":"62","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. 25-Hydroxycholesterol 3-sulfate is an endogenous ligand of DNA methyltransferases in hepatocytes. J. Lipid Res. 62, 100063 (2021).","journal-title":"J. Lipid Res"},{"key":"1651_CR51","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.3390\/ijerph16152791","volume":"16","author":"S Tommasi","year":"2019","unstructured":"Tommasi, S. & Besaratinia, A. DNA Hydroxymethylation at the Interface of the Environment and Nonalcoholic Fatty Liver Disease. Int J. Environ. Res Public Health 16, 2791 (2019).","journal-title":"Int J. Environ. Res Public Health"},{"key":"1651_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.873699","volume":"13","author":"Y Ren","year":"2022","unstructured":"Ren, Y. et al. Adipokines, hepatokines and myokines: focus on their role and molecular mechanisms in adipose tissue inflammation. Front Endocrinol. (Lausanne) 13, 873699 (2022).","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"1651_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2337\/db15-1716","volume":"66","author":"C Baumeier","year":"2017","unstructured":"Baumeier, C. et al. Hepatic DPP4 DNA methylation associates with fatty liver. Diabetes 66, 25\u201335 (2017).","journal-title":"Diabetes"},{"key":"1651_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-06614-9","volume":"12","author":"R Gallego-Dur\u00e1n","year":"2022","unstructured":"Gallego-Dur\u00e1n, R. et al. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. Sci. Rep. 12, 3418 (2022).","journal-title":"Sci. Rep."},{"key":"1651_CR55","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jhep.2018.06.023","volume":"69","author":"F De Chiara","year":"2018","unstructured":"De Chiara, F. et al. Urea cycle dysregulation in non-alcoholic fatty liver disease. J. Hepatol. 69, 905\u2013915 (2018).","journal-title":"J. Hepatol."},{"key":"1651_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100780","volume":"5","author":"KL Thomsen","year":"2023","unstructured":"Thomsen, K. L. et al. Role of ammonia in NAFLD: An unusual suspect. JHEP Rep. 5, 100780 (2023).","journal-title":"JHEP Rep."},{"key":"1651_CR57","first-page":"278","volume":"12","author":"P Gallo","year":"2024","unstructured":"Gallo, P. et al. Approaching the Sarcopenic Patient with Nonalcoholic Steatohepatitis-related Cirrhosis. J. Clin. Transl. Hepatol. 12, 278\u2013286 (2024).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"1651_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206068","volume":"10","author":"S Wang","year":"2023","unstructured":"Wang, S. et al. Epigenetic regulation of hepatic lipid metabolism by DNA methylation. Adv. Sci. (Weinh). 10, e2206068 (2023).","journal-title":"Adv. Sci. (Weinh)"},{"key":"1651_CR59","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1136\/gutjnl-2012-302962","volume":"62","author":"CJ Pirola","year":"2013","unstructured":"Pirola, C. J. et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut. 62, 1356\u20131363 (2013).","journal-title":"Gut"},{"key":"1651_CR60","doi-asserted-by":"crossref","unstructured":"Li, Y., Chen, X. & Lu, C. The interplay between DNA and histone methylation: molecular mechanisms and disease implications. 22, e51803. (2021).","DOI":"10.15252\/embr.202051803"},{"key":"1651_CR61","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mam.2016.11.008","volume":"54","author":"J Lee","year":"2017","unstructured":"Lee, J., Kim, Y., Friso, S. & Choi, S. W. Epigenetics in non-alcoholic fatty liver disease. Mol. Asp. Med. 54, 78\u201388 (2017).","journal-title":"Mol. Asp. Med"},{"key":"1651_CR62","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/ijms19030911","volume":"19","author":"JA Del Campo","year":"2018","unstructured":"Del Campo, J. A., Gallego-Dur\u00e1n, R., Gallego, P. & Grande, L. Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD). Int J. Mol. Sci. 19, 911 (2018).","journal-title":"Int J. Mol. Sci."},{"key":"1651_CR63","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/ars.2016.6808","volume":"27","author":"S Zhong","year":"2017","unstructured":"Zhong, S. et al. Cluster of differentiation 36 deficiency aggravates macrophage infiltration and hepatic inflammation by upregulating monocyte chemotactic protein-1 expression of hepatocytes through histone deacetylase 2-dependent pathway. Antioxid. Redox Signal 27, 201\u2013214 (2017).","journal-title":"Antioxid. Redox Signal"},{"key":"1651_CR64","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nature08197","volume":"460","author":"T Finkel","year":"2009","unstructured":"Finkel, T., Deng, C. X. & Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature 460, 587\u2013591 (2009).","journal-title":"Nature"},{"key":"1651_CR65","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3390\/ijms22020689","volume":"22","author":"F Chleilat","year":"2021","unstructured":"Chleilat, F., Schick, A., Deleemans, J. M. & Reimer, R. A. Paternal methyl donor supplementation in rats improves fertility, physiological outcomes, gut microbial signatures and epigenetic markers altered by high fat\/high sucrose diet. Int J. Mol. Sci. 22, 689 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"1651_CR66","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.31773","volume":"74","author":"H Ren","year":"2021","unstructured":"Ren, H. et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4\u03b1. Hepatology 74, 723\u2013740 (2021).","journal-title":"Hepatology"},{"key":"1651_CR67","doi-asserted-by":"publisher","first-page":"11085","DOI":"10.3390\/ijms222011085","volume":"22","author":"JH Kim","year":"2021","unstructured":"Kim, J. H., Nagappan, A., Jung, D. Y., Suh, N. & Jung, M. H. Histone demethylase KDM7A contributes to the development of hepatic steatosis by targeting diacylglycerol acyltransferase 2. Int J. Mol. Sci. 22, 11085 (2021).","journal-title":"Int J. Mol. Sci."},{"key":"1651_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31953-x","volume":"8","author":"JH Kim","year":"2018","unstructured":"Kim, J. H., Jung, D. Y., Nagappan, A. & Jung, M. H. Histone H3K9 demethylase JMJD2B induces hepatic steatosis through upregulation of PPAR\u03b32. Sci. Rep. 8, 13734 (2018).","journal-title":"Sci. Rep."},{"key":"1651_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04361-y","volume":"9","author":"J Bricambert","year":"2018","unstructured":"Bricambert, J. et al. The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. Nat. Commun. 9, 2092 (2018).","journal-title":"Nat. Commun."},{"key":"1651_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114265","volume":"442","author":"X Fan","year":"2024","unstructured":"Fan, X., Wang, H., Wang, W., Shen, J. & Wang, Z. Exercise training alleviates cholesterol and lipid accumulation in mice with non-alcoholic steatohepatitis: Reduction of KMT2D-mediated histone methylation of IDI1. Exp. Cell Res. 442, 114265 (2024).","journal-title":"Exp. Cell Res"},{"key":"1651_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14384-z","volume":"11","author":"S Byun","year":"2020","unstructured":"Byun, S. et al. Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase. Nat. Commun. 11, 807 (2020).","journal-title":"Nat. Commun."},{"key":"1651_CR72","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1172\/JCI97736","volume":"128","author":"S Seok","year":"2018","unstructured":"Seok, S. et al. Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid \u03b2-oxidation. J. Clin. Invest 128, 3144\u20133159 (2018).","journal-title":"J. Clin. Invest"},{"key":"1651_CR73","doi-asserted-by":"crossref","unstructured":"Lee, J., An, H., Kim, C. S. & Lee, S. The methyltransferase MLL4 promotes non-alcoholic steatohepatitis by enhancing NF-\u03baB signaling. J. Biol. Chem. 107984 10.1016\/j.jbc.2024.107984 (2024).","DOI":"10.1016\/j.jbc.2024.107984"},{"key":"1651_CR74","doi-asserted-by":"publisher","first-page":"8617","DOI":"10.3390\/ijms21228617","volume":"21","author":"HJ Lim","year":"2020","unstructured":"Lim, H. J. & Kim, M. EZH2 as a Potential Target for NAFLD Therapy. Int J. Mol. Sci. 21, 8617 (2020).","journal-title":"Int J. Mol. Sci."},{"key":"1651_CR75","doi-asserted-by":"publisher","first-page":"R4","DOI":"10.1093\/hmg\/ddac088","volume":"31","author":"G Qian","year":"2022","unstructured":"Qian, G. & Morral, N. Role of non-coding RNAs on liver metabolism and NAFLD pathogenesis. Hum. Mol. Genet 31, R4\u2013R21 (2022).","journal-title":"Hum. Mol. Genet"},{"key":"1651_CR76","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/gutjnl-2020-322526","volume":"70","author":"X Wang","year":"2021","unstructured":"Wang, X., He, Y., Mackowiak, B. & Gao, B. MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases. Gut 70, 784\u2013795 (2021).","journal-title":"Gut"},{"key":"1651_CR77","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/apha.12681","volume":"219","author":"S Vienberg","year":"2017","unstructured":"Vienberg, S., Geiger, J., Madsen, S. & Dalgaard, L. T. MicroRNAs in metabolism. Acta Physiol. (Oxf). 219, 346\u2013361 (2017).","journal-title":"Acta Physiol. (Oxf)"},{"key":"1651_CR78","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","volume":"62","author":"S Bandiera","year":"2015","unstructured":"Bandiera, S., Pfeffer, S., Baumert, T. F. & Zeisel, M. B. miR-122\u2013a key factor and therapeutic target in liver disease. J. Hepatol. 62, 448\u2013457 (2015).","journal-title":"J. Hepatol."},{"key":"1651_CR79","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.7150\/ijbs.57610","volume":"17","author":"H Liu","year":"2021","unstructured":"Liu, H., Niu, Q., Wang, T., Dong, H. & Bian, C. Lipotoxic hepatocytes promote nonalcoholic fatty liver disease progression by delivering microRNA-9-5p and activating macrophages. Int J. Biol. Sci. 17, 3745\u20133759 (2021).","journal-title":"Int J. Biol. Sci."},{"key":"1651_CR80","doi-asserted-by":"publisher","first-page":"6167","DOI":"10.1111\/jcmm.13902","volume":"22","author":"D Ye","year":"2018","unstructured":"Ye, D., Lou, G., Zhang, T., Dong, F. & Liu, Y. MiR-17 family-mediated regulation of Pknox1 influences hepatic steatosis and insulin signaling. J. Cell Mol. Med. 22, 6167\u20136175 (2018).","journal-title":"J. Cell Mol. Med"},{"key":"1651_CR81","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3892\/ijmm.2015.2076","volume":"35","author":"C Sun","year":"2015","unstructured":"Sun, C. et al. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J. Mol. Med. 35, 847\u2013853 (2015).","journal-title":"Int J. Mol. Med"},{"key":"1651_CR82","first-page":"715","volume":"9","author":"CP Li","year":"2017","unstructured":"Li, C. P., Li, H. J., Nie, J., Chen, X. & Zhou, X. Mutation of miR-21 targets endogenous lipoprotein receptor-related protein 6 and nonalcoholic fatty liver disease. Am. J. Transl. Res. 9, 715\u2013721 (2017).","journal-title":"Am. J. Transl. Res"},{"key":"1651_CR83","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1136\/gutjnl-2014-308430","volume":"65","author":"H Wu","year":"2016","unstructured":"Wu, H., Ng, R., Chen, X., Steer, C. J. & Song, G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut 65, 1850\u20131860 (2016).","journal-title":"Gut"},{"key":"1651_CR84","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/JME-20-0324","volume":"68","author":"L Li","year":"2021","unstructured":"Li, L. et al. miR-23a\/b-3p promotes hepatic lipid accumulation by regulating Srebp-1c and Fas. J. Mol. Endocrinol. 68, 35\u201349 (2021).","journal-title":"J. Mol. Endocrinol."},{"key":"1651_CR85","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/hep.27153","volume":"60","author":"R Ng","year":"2014","unstructured":"Ng, R. et al. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology 60, 554\u2013564 (2014).","journal-title":"Hepatology"},{"key":"1651_CR86","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/iub.2221","volume":"72","author":"M Teimouri","year":"2020","unstructured":"Teimouri, M. et al. Inhibiting miR-27a and miR-142-5p attenuate nonalcoholic fatty liver disease by regulating Nrf2 signaling pathway. IUBMB Life 72, 361\u2013372 (2020).","journal-title":"IUBMB Life"},{"key":"1651_CR87","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s42003-023-05049-w","volume":"6","author":"E Sakai","year":"2023","unstructured":"Sakai, E. et al. miR-27b targets MAIP1 to mediate lipid accumulation in cultured human and mouse hepatic cells. Commun. Biol. 6, 669 (2023).","journal-title":"Commun. Biol."},{"key":"1651_CR88","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12944-020-01261-3","volume":"19","author":"Q Zhang","year":"2020","unstructured":"Zhang, Q. et al. MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line. Lipids Health Dis. 19, 76 (2020).","journal-title":"Lipids Health Dis."},{"key":"1651_CR89","doi-asserted-by":"publisher","first-page":"13450","DOI":"10.18632\/oncotarget.14561","volume":"8","author":"J Fan","year":"2017","unstructured":"Fan, J. et al. MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db\/db) mice via down-regulating FASN. Oncotarget 8, 13450\u201313463 (2017).","journal-title":"Oncotarget"},{"key":"1651_CR90","doi-asserted-by":"publisher","first-page":"e0158657","DOI":"10.1371\/journal.pone.0158657","volume":"11","author":"XF Tian","year":"2016","unstructured":"Tian, X. F., Ji, F. J., Zang, H. L. & Cao, H. Activation of the miR-34a\/SIRT1\/p53 signaling pathway contributes to the progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs. PLoS One 11, e0158657 (2016).","journal-title":"PLoS One"},{"key":"1651_CR91","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jhep.2012.08.008","volume":"58","author":"RE Castro","year":"2013","unstructured":"Castro, R. E. et al. miR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J. Hepatol. 58, 119\u2013125 (2013).","journal-title":"J. Hepatol."},{"key":"1651_CR92","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.3390\/nu15214616","volume":"15","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. MicroRNA-34a Mediates High-Fat-Induced Hepatic Insulin Resistance by Targeting ENO3. Nutrients 15, 4616 (2023).","journal-title":"Nutrients"},{"key":"1651_CR93","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41420-021-00536-7","volume":"7","author":"W Wang","year":"2021","unstructured":"Wang, W. et al. Exosomes secreted by palmitic acid-treated hepatocytes promote LX-2 cell activation by transferring miRNA-107. Cell Death Discov. 7, 174 (2021).","journal-title":"Cell Death Discov."},{"key":"1651_CR94","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","volume":"25","author":"JK Long","year":"2019","unstructured":"Long, J. K., Dai, W., Zheng, Y. W. & Zhao, S. P. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol. Med. 25, 26 (2019).","journal-title":"Mol. Med."},{"key":"1651_CR95","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","volume":"64","author":"CJ Pirola","year":"2015","unstructured":"Pirola, C. J. et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64, 800\u2013812 (2015).","journal-title":"Gut"},{"key":"1651_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2293-7","volume":"11","author":"X Jin","year":"2020","unstructured":"Jin, X. et al. Antagonizing circRNA_002581-miR-122-CPEB1 axis alleviates NASH through restoring PTEN-AMPK-mTOR pathway regulated autophagy. Cell Death Dis. 11, 123 (2020).","journal-title":"Cell Death Dis."},{"key":"1651_CR97","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/hep.31871","volume":"74","author":"L Chen","year":"2021","unstructured":"Chen, L. et al. Inhibition of Secretin\/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. Hepatology 74, 1845\u20131863 (2021).","journal-title":"Hepatology"},{"key":"1651_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100584","volume":"27","author":"SS Jin","year":"2022","unstructured":"Jin, S. S., Lin, C. J., Lin, X. F., Zheng, J. Z. & Guan, H. Q. Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p\/c-Jun\/SREBP-1c pathway. Ann. Hepatol. 27, 100584 (2022).","journal-title":"Ann. Hepatol."},{"key":"1651_CR99","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/jgh.12878","volume":"30","author":"W Jiang","year":"2015","unstructured":"Jiang, W. et al. MiR-146b attenuates high-fat diet-induced non-alcoholic steatohepatitis in mice. J. Gastroenterol. Hepatol. 30, 933\u2013943 (2015).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1651_CR100","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12876-020-01189-z","volume":"20","author":"S Chen","year":"2020","unstructured":"Chen, S. et al. Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p\/FGF21 axis. BMC Gastroenterol. 20, 39 (2020).","journal-title":"BMC Gastroenterol."},{"key":"1651_CR101","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3389\/fgene.2019.00484","volume":"10","author":"Z Huang","year":"2019","unstructured":"Huang, Z. et al. Transcriptional Repression of CYP3A4 by Increased miR-200a-3p and miR-150-5p Promotes Steatosis in vitro. Front Genet 10, 484 (2019).","journal-title":"Front Genet"},{"key":"1651_CR102","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.bbrc.2017.10.149","volume":"494","author":"B Zhuge","year":"2017","unstructured":"Zhuge, B. & Li, G. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator. Biochem Biophys. Res Commun. 494, 687\u2013692 (2017).","journal-title":"Biochem Biophys. Res Commun."},{"key":"1651_CR103","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.bbrc.2017.09.042","volume":"493","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. MiR-181b regulates steatosis in nonalcoholic fatty liver disease via targeting SIRT1. Biochem Biophys. Res Commun. 493, 227\u2013232 (2017).","journal-title":"Biochem Biophys. Res Commun."},{"key":"1651_CR104","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.bbrc.2018.12.061","volume":"508","author":"R Huang","year":"2019","unstructured":"Huang, R. et al. Upregulation of miR-181a impairs lipid metabolism by targeting PPAR\u03b1 expression in nonalcoholic fatty liver disease. Biochem Biophys. Res Commun. 508, 1252\u20131258 (2019).","journal-title":"Biochem Biophys. Res Commun."},{"key":"1651_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.119011","volume":"268","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. Obesity-induced upregulation of microRNA-183-5p promotes hepatic triglyceride accumulation by targeting the B-cell translocation gene 1. Life Sci. 268, 119011 (2021).","journal-title":"Life Sci."},{"key":"1651_CR106","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/biom14010034","volume":"14","author":"L Ma","year":"2023","unstructured":"Ma, L., Song, H., Zhang, C. Y. & Hou, D. MiR-192-5p Ameliorates Hepatic Lipid Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting Yy1. Biomolecules 14, 34 (2023).","journal-title":"Biomolecules"},{"key":"1651_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100179","volume":"2","author":"Z Wang","year":"2020","unstructured":"Wang, Z. et al. Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor. JHEP Rep. 2, 100179 (2020).","journal-title":"JHEP Rep."},{"key":"1651_CR108","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1016\/j.bbadis.2017.09.020","volume":"1863","author":"H Nie","year":"2017","unstructured":"Nie, H. et al. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR. Biochim Biophys. Acta Mol. Basis Dis. 1863, 3087\u20133094 (2017).","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"key":"1651_CR109","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/labinvest.2010.166","volume":"91","author":"A Alisi","year":"2011","unstructured":"Alisi, A. et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 91, 283\u2013293 (2011).","journal-title":"Lab Invest"},{"key":"1651_CR110","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aao4617","volume":"11","author":"JM Wang","year":"2018","unstructured":"Wang, J. M. et al. IRE1\u03b1 prevents hepatic steatosis by processing and promoting the degradation of select microRNAs. Sci. Signal 11, eaao4617 (2018).","journal-title":"Sci. Signal"},{"key":"1651_CR111","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11010-021-04269-0","volume":"477","author":"MJ Hu","year":"2022","unstructured":"Hu, M. J., Long, M. & Dai, R. J. Acetylation of H3K27 activated lncRNA NEAT1 and promoted hepatic lipid accumulation in non-alcoholic fatty liver disease via regulating miR-212-5p\/GRIA3. Mol. Cell Biochem 477, 191\u2013203 (2022).","journal-title":"Mol. Cell Biochem"},{"key":"1651_CR112","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1530\/JME-16-0179","volume":"59","author":"Y Guo","year":"2017","unstructured":"Guo, Y. et al. miR-212-5p suppresses lipid accumulation by targeting FAS and SCD1. J. Mol. Endocrinol. 59, 205\u2013217 (2017).","journal-title":"J. Mol. Endocrinol."},{"key":"1651_CR113","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/jcmm.12733","volume":"20","author":"J Xiao","year":"2016","unstructured":"Xiao, J. et al. miR-212 downregulation contributes to the protective effect of exercise against non-alcoholic fatty liver via targeting FGF-21. J. Cell Mol. Med. 20, 204\u2013216 (2016).","journal-title":"J. Cell Mol. Med"},{"key":"1651_CR114","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.hbpd.2019.05.002","volume":"18","author":"JJ Wang","year":"2019","unstructured":"Wang, J. J., Zhang, Y. T., Tseng, Y. J. & Zhang, J. miR-222 targets ACOX1, promotes triglyceride accumulation in hepatocytes. Hepatobiliary Pancreat. Dis. Int. 18, 360\u2013365 (2019).","journal-title":"Hepatobiliary Pancreat. Dis. Int"},{"key":"1651_CR115","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/1440-1681.12940","volume":"45","author":"L Lei","year":"2018","unstructured":"Lei, L., Zhou, C., Yang, X. & Li, L. Down-regulation of microRNA-375 regulates adipokines and inhibits inflammatory cytokines by targeting AdipoR2 in non-alcoholic fatty liver disease. Clin. Exp. Pharm. Physiol. 45, 819\u2013831 (2018).","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"1651_CR116","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.metabol.2018.03.023","volume":"85","author":"T Zhang","year":"2018","unstructured":"Zhang, T., Zhao, X., Steer, C. J., Yan, G. & Song, G. A negative feedback loop between microRNA-378 and Nrf1 promotes the development of hepatosteatosis in mice treated with a high fat diet. Metabolism 85, 183\u2013191 (2018).","journal-title":"Metabolism"},{"key":"1651_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05283-8","volume":"22","author":"L Yang","year":"2024","unstructured":"Yang, L. et al. Exosomes regulate SIRT3-related autophagy by delivering miR-421 to regulate macrophage polarization and participate in OSA-related NAFLD. J. Transl. Med. 22, 475 (2024).","journal-title":"J. Transl. Med"},{"key":"1651_CR118","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.biocel.2015.04.016","volume":"64","author":"W Hur","year":"2015","unstructured":"Hur, W. et al. Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK\/AKT pathway. Int J. Biochem Cell Biol. 64, 265\u2013276 (2015).","journal-title":"Int J. Biochem Cell Biol."},{"key":"1651_CR119","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jcmgh.2021.06.007","volume":"12","author":"J Ahn","year":"2021","unstructured":"Ahn, J. et al. 6-Gingerol Ameliorates Hepatic Steatosis via HNF4\u03b1\/miR-467b-3p\/GPAT1 Cascade. Cell Mol. Gastroenterol. Hepatol. 12, 1201\u20131213 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"1651_CR120","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1124\/dmd.106.009670","volume":"34","author":"MT Donato","year":"2006","unstructured":"Donato, M. T. et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab. Dispos. 34, 1556\u20131562 (2006).","journal-title":"Drug Metab. Dispos."},{"key":"1651_CR121","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3350\/cmh.2020.0166","volume":"26","author":"S Han","year":"2020","unstructured":"Han, S. et al. Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease. Clin. Mol. Hepatol. 26, 705\u2013714 (2020).","journal-title":"Clin. Mol. Hepatol."},{"key":"1651_CR122","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2023.2239592","volume":"18","author":"Y Dong","year":"2023","unstructured":"Dong, Y., Hu, M., Tan, K. & Dai, R. ZNF143 inhibits hepatocyte mitophagy and promotes non-alcoholic fatty liver disease by targeting increased lncRNA NEAT1 expression to activate ROCK2 pathway. Epigenetics 18, 2239592 (2023).","journal-title":"Epigenetics"},{"key":"1651_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.858558","volume":"10","author":"J Xiang","year":"2022","unstructured":"Xiang, J., Deng, Y. Y., Liu, H. X. & Pu, Y. LncRNA MALAT1 promotes PPAR\u03b1\/CD36-mediated hepatic lipogenesis in nonalcoholic fatty liver disease by modulating miR-206\/ARNT axis. Front Bioeng. Biotechnol. 10, 858558 (2022).","journal-title":"Front Bioeng. Biotechnol."},{"key":"1651_CR124","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/d41586-024-03683-w","volume":"635","author":"A Dance","year":"2024","unstructured":"Dance, A. Circular logic: understanding RNA\u2019s strangest form yet. Nature 635, 511\u2013513 (2024).","journal-title":"Nature"},{"key":"1651_CR125","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3390\/ijms24021297","volume":"24","author":"CH Liu","year":"2023","unstructured":"Liu, C. H. et al. CircRNA-PI4KB induces hepatic lipid deposition in non-alcoholic fatty liver disease by transporting mirna-122 to extra-hepatocytes. Int J. Mol. Sci. 24, 1297 (2023).","journal-title":"Int J. Mol. Sci."},{"key":"1651_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-01108-8","volume":"19","author":"J Li","year":"2021","unstructured":"Li, J. et al. A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p\/miR-320a and ABCA1\/CPT1 axis. J. Nanobiotechnology 19, 363 (2021).","journal-title":"J. Nanobiotechnology"},{"key":"1651_CR127","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12944-022-01740-9","volume":"21","author":"X Yuan","year":"2022","unstructured":"Yuan, X. et al. CircLDLR acts as a sponge for miR-667-5p to regulate SIRT1 expression in non-alcoholic fatty liver disease. Lipids Health Dis. 21, 127 (2022).","journal-title":"Lipids Health Dis."},{"key":"1651_CR128","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.tig.2021.06.014","volume":"38","author":"RL Kan","year":"2022","unstructured":"Kan, R. L., Chen, J. & Sallam, T. Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation. Trends Genet 38, 182\u2013193 (2022).","journal-title":"Trends Genet"},{"key":"1651_CR129","doi-asserted-by":"publisher","first-page":"e0046","DOI":"10.1097\/HC9.0000000000000046","volume":"7","author":"J Tan","year":"2023","unstructured":"Tan, J. et al. Roles of RNA m6A modification in nonalcoholic fatty liver disease. Hepatol. Commun. 7, e0046 (2023).","journal-title":"Hepatol. Commun."},{"key":"1651_CR130","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbrc.2019.08.018","volume":"518","author":"W Xie","year":"2019","unstructured":"Xie, W., Ma, L. L., Xu, Y. Q., Wang, B. H. & Li, S. M. METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism. Biochem Biophys. Res Commun. 518, 120\u2013126 (2019).","journal-title":"Biochem Biophys. Res Commun."},{"key":"1651_CR131","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/hep.31220","volume":"73","author":"B Zhou","year":"2021","unstructured":"Zhou, B. et al. N6 -Methyladenosine reader protein YT521-B homology domain-containing 2 suppresses liver steatosis by regulation of mrna stability of lipogenic genes. Hepatology 73, 91\u2013103 (2021).","journal-title":"Hepatology"},{"key":"1651_CR132","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41576-018-0089-8","volume":"20","author":"SL Klemm","year":"2019","unstructured":"Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory epigenome. Nat. Rev. Genet 20, 207\u2013220 (2019).","journal-title":"Nat. Rev. Genet"},{"key":"1651_CR133","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jhep.2022.07.017","volume":"77","author":"C Tian","year":"2022","unstructured":"Tian, C. et al. MRG15 aggravates non-alcoholic steatohepatitis progression by regulating the mitochondrial proteolytic degradation of TUFM. J. Hepatoln 77, 1491\u20131503 (2022).","journal-title":"J. Hepatoln"},{"key":"1651_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111071","volume":"40","author":"Q Yin","year":"2022","unstructured":"Yin, Q. et al. RPA1 controls chromatin architecture and maintains lipid metabolic homeostasis. Cell Rep. 40, 111071 (2022).","journal-title":"Cell Rep."},{"key":"1651_CR135","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/cells10061355","volume":"10","author":"T Hajri","year":"2021","unstructured":"Hajri, T., Zaiou, M., Fungwe, T. V., Ouguerram, K. & Besong, S. Epigenetic regulation of peroxisome proliferator-activated receptor gamma mediates high-fat diet-induced non-alcoholic fatty liver disease. Cells 10, 1355 (2021).","journal-title":"Cells"},{"key":"1651_CR136","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1136\/gutjnl-2016-311526","volume":"66","author":"T Hardy","year":"2017","unstructured":"Hardy, T. et al. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut. 66, 1321\u20131328 (2017).","journal-title":"Gut"},{"key":"1651_CR137","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1136\/gut.2009.204354","volume":"59","author":"Y Jung","year":"2010","unstructured":"Jung, Y. et al. Signals from dying hepatocytes trigger growth of liver progenitors. Gut 59, 655\u2013665 (2010).","journal-title":"Gut"},{"key":"1651_CR138","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/biom14030277","volume":"14","author":"A Ferro","year":"2024","unstructured":"Ferro, A. et al. Extracellular vesicles as delivery vehicles for non-coding rnas: potential biomarkers for chronic liver diseases. Biomolecules 14, 277 (2024).","journal-title":"Biomolecules"},{"key":"1651_CR139","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/biomedicines10010195","volume":"10","author":"LA Newman","year":"2022","unstructured":"Newman, L. A. et al. Selective isolation of liver-derived extracellular vesicles redefines performance of mirna biomarkers for non-alcoholic fatty liver disease. Biomedicines 10, 195 (2022).","journal-title":"Biomedicines"},{"key":"1651_CR140","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12876-020-01334-8","volume":"20","author":"S Xin","year":"2020","unstructured":"Xin, S., Zhan, Q., Chen, X., Xu, J. & Yu, Y. Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis. BMC Gastroenterol. 20, 186 (2020).","journal-title":"BMC Gastroenterol."},{"key":"1651_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105484","volume":"167","author":"N Sodum","year":"2021","unstructured":"Sodum, N., Kumar, G., Bojja, S. L., Kumar, N. & Rao, C. M. Epigenetics in MASLD\/NASH: Targets and therapy. Pharm. Res. 167, 105484 (2021).","journal-title":"Pharm. Res"},{"key":"1651_CR142","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.2337\/db14-0263","volume":"63","author":"F Xu","year":"2014","unstructured":"Xu, F. et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 63, 3637\u20133646 (2014).","journal-title":"Diabetes"},{"key":"1651_CR143","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1159\/000495898","volume":"51","author":"R Zhou","year":"2018","unstructured":"Zhou, R. et al. Resveratrol ameliorates lipid droplet accumulation in liver through a sirt1\/ atf6-dependent mechanism. Cell Physiol. Biochem 51, 2397\u20132420 (2018).","journal-title":"Cell Physiol. Biochem"},{"key":"1651_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2019.105667","volume":"119","author":"H Hosseini","year":"2020","unstructured":"Hosseini, H. et al. Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. Int J. Biochem Cell Biol. 119, 105667 (2020).","journal-title":"Int J. Biochem Cell Biol."},{"key":"1651_CR145","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/jn\/nxaa032","volume":"150","author":"RP da Silva","year":"2020","unstructured":"da Silva, R. P., Eudy, B. J. & Deminice, R. One-carbon metabolism in fatty liver disease and fibrosis: one-carbon to rule them all. J. Nutr. 150, 994\u20131003 (2020).","journal-title":"J. Nutr."},{"key":"1651_CR146","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1476-511X-12-34","volume":"12","author":"L Wang","year":"2013","unstructured":"Wang, L. et al. Betaine supplement alleviates hepatic triglyceride accumulation of apolipoprotein E deficient mice via reducing methylation of peroxisomal proliferator-activated receptor alpha promoter. Lipids Health Dis. 12, 34 (2013).","journal-title":"Lipids Health Dis."},{"key":"1651_CR147","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jnutbio.2013.11.007","volume":"25","author":"LJ Wang","year":"2014","unstructured":"Wang, L. J. et al. Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet. J. Nutr. Biochem 25, 329\u2013336 (2014).","journal-title":"J. Nutr. Biochem"},{"key":"1651_CR148","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/hep.23239","volume":"50","author":"MF Abdelmalek","year":"2009","unstructured":"Abdelmalek, M. F. et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50, 1818\u20131826 (2009).","journal-title":"Hepatology"},{"key":"1651_CR149","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11596-019-1997-3","volume":"39","author":"YP Zhang","year":"2019","unstructured":"Zhang, Y. P. et al. Berberine ameliorates high-fat diet-induced non-alcoholic fatty liver disease in rats via activation of SIRT3\/AMPK\/ACC pathway. Curr. Med Sci. 39, 37\u201343 (2019).","journal-title":"Curr. Med Sci."},{"key":"1651_CR150","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2018.02.035","volume":"825","author":"CH Li","year":"2018","unstructured":"Li, C. H. et al. Berberine induces miR-373 expression in hepatocytes to inactivate hepatic steatosis associated AKT-S6 kinase pathway. Eur. J. Pharm. 825, 107\u2013118 (2018).","journal-title":"Eur. J. Pharm."},{"key":"1651_CR151","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.cmet.2018.01.007","volume":"27","author":"X Ouyang","year":"2018","unstructured":"Ouyang, X. et al. Digoxin suppresses pyruvate kinase m2-promoted hif-1\u03b1 transactivation in steatohepatitis. Cell Metab. 27, 339\u2013350 (2018).","journal-title":"Cell Metab."},{"key":"1651_CR152","doi-asserted-by":"publisher","first-page":"G387","DOI":"10.1152\/ajpgi.00054.2019","volume":"317","author":"P Zhao","year":"2019","unstructured":"Zhao, P. et al. Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation. Am. J. Physiol. Gastrointest. Liver Physiol. 317, G387\u2013G397 (2019).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1651_CR153","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","volume":"178","author":"DA Jaitin","year":"2019","unstructured":"Jaitin, D. A. et al. Lipid-associated macrophages control metabolic homeostasis in a trem2-dependent manner. Cell 178, 686\u2013698.e14 (2019).","journal-title":"Cell"},{"key":"1651_CR154","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1620\/tjem.229.35","volume":"229","author":"Q Zhao","year":"2013","unstructured":"Zhao, Q., Qin, C. Y., Zhao, Z. H., Fan, Y. C. & Wang, K. Epigenetic modifications in hepatic stellate cells contribute to liver fibrosis. Tohoku J. Exp. Med. 229, 35\u201343 (2013).","journal-title":"Tohoku J. Exp. Med"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01651-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01651-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:03:34Z","timestamp":1778551414000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01651-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":154,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1651"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01651-1","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}